Navigation Links
Andromeda Biotech: A drug for type 1 diabetes
Date:11/22/2011

The clinical trial was random, regulated, double-blinded and broad-based. The drug was tested on 457 patients, aged 16-45, who had been diagnosed with Type 1 diabetes a short time before joining the trial. The trial took place in around 40 medical centers in Europe, Israel and South Africa. The patients in the trial were randomly assigned to one of two groups: One received the trial drug (DiaPep277) through a subcutaneous injection once every three months, for a period of two years, while the control group was given a placebo in the same way. In addition, all of the patients received insulin as needed to stabilize their glucose levels.

DiaPep277 was invented by Prof. Irun Cohen and his team at the Weizmann Institute of Science. This unique peptide, containing 24 amino acids, is derived from the sequence of the human heat shock protein 60 (Hsp60). The peptide acts by modulating the immune system, preventing the destruction of the pancreatic cells that secrete insulin and preserving their natural function. Treatment of Type 1 diabetes patients with DiaPep277 may have several medical benefits: slowing the deterioration of the diseased tissue, improved metabolic control, a reduction in daily insulin requirements and fewer complications of diabetes.

During the trial, the ability of the patients' pancreas to secrete insulin was tested. From an initial analysis of the results, it appears that the patients treated with the drug for a year or more had significantly higher pancreas function than those in the control group.

From the point of view of safety, no significant differences were found in the incidence of side effects between the treated and control groups.

Additional data on the drug's efficacy and safety were collected and evaluated, and these will be presented in a final report on the trial, which will be completed in several months.

Andromeda Biotech is now planning to conduct another trial, to try to reproduce these results. Recruitment of patients into this trial is expected to be finalized in the second quarter of 2012. The research and development team of Andromeda Biotech emphasize that the drug is still under development, and there is no absolute guarantee that the drug will eventually be marketed.


'/>"/>
Contact: Yivsam Azgad
news@weizmann.ac.il
972-893-43856
Weizmann Institute of Science
Source:Eurekalert

Related biology news :

1. Vegetarian diet, physical activity protect against diabetes in black population, study shows
2. Animal study suggests that newborn period may be crucial time to prevent later diabetes
3. VTT identified specific bacteria which precede autoimmune diabetes
4. Joslin study finds clue to birth defects in babies of mothers with diabetes
5. Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity
6. Pitt team identifies key protein causing excess liver production of glucose in diabetes
7. Discovery of insulin switches in pancreas could lead to new diabetes drugs
8. Clues to finding further causes for monogenic diabetes
9. MU study links inactivity with risk factors for Type 2 diabetes
10. Joslin researchers identify new target for treatment of type 2 diabetes and prediabetes
11. How fatty diets cause diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... 4, 2017  CES 2017 – Valencell , ... today announced the launch of two new versions ... highly-accurate biometric sensor modules that incorporate the best ... and expertise. The two new designs include Benchmark ... hearables, and Benchmark BW2.0, a 2-LED version of ...
(Date:12/22/2016)... 2016  As part of its longstanding mission to improve ... company, recently released its latest children,s book, titled ... on the topics of inheritance and variation of traits that ... in elementary school classrooms in the US. ... Ariana Killoran , whose previous book with 23andMe, ...
(Date:12/20/2016)... 2016 The rising popularity of mobility ... is stoking significant interest in keyless access systems. ... low energy (BLE), biometrics and near-field communication (NFC) ... of wireless technologies in the automotive industry. This ... access systems opens the market to specialist companies ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... -- Shareholder rights law firm Johnson & Weaver, LLP ... of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ) ... sale of the Company to Eli Lilly and Company. ... for the acute treatment of migraines. On ... definitive merger agreement with Eli Lilly. Under the terms ...
(Date:1/18/2017)...  Market Research Future published a half-cooked research report on Global ... at a CAGR of 12% during the period 2016 to 2022. ... ... cell division without any control. These abnormal cells have the ability ... cells can spread to other parts of the body through the ...
(Date:1/17/2017)... Jan. 17, 2017  An international team of ... and St. Boniface Hospital Albrechtsen Research Centre/University of ... an unmet health need affecting nearly one in ... Clinical Investigation, their results identify small molecule drugs ... reverse neuronal injury in animal models of metabolic, ...
(Date:1/17/2017)... Noom Inc. , the leader ... offer fully Spanish behavior change programs that address ... prevention and healthy weight management programs  have ... interventions among Hispanic Americans who are at increased ... database, program-specific curriculum content and program features are ...
Breaking Biology Technology: